Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects

Inclusion Criteria: * Provision of written informed consent * Undergone a total mastectomy, a lumpectomy or a quadrantectomy for primary breast cancer +/-chemo, +/-radiotherapy * Have commenced anastrozole therapy within the previous 6 months * Presence of node negative or positive disease * Receptor-positive tumors, defined as ER ≥10% of the tumor cells positive by immunocytochemical evaluation * Postmenopausal whether induced by surgery, radiotherapy (chemotherapy-induced amenorrhea may be difficult to determine they may be amenorrhoeic but still have functioning ovaries), or by being naturally amenorrhoeic, for 1 year or more if younger than 50 and for 6 months if 50 or older * Postmenopausal levels of FSH/LH/E2 (follicle stimulating hormone, luteinizing hormone, oestrogen) according to the definition of "postmenopausal range" for the laboratory involved * Have developed arthralgia and associated joint symptoms whilst being treated with anastrozole with a score of 40mm or greater on a pain and stiffness 100mm VAS * WBC ≥ 3.0 x 109/L, granulocytes ≥ 1.5 X 109/L and platelets ≥ 100 x 109/L. * AST/SGOT or ALT/SGPT ≤ 3 times ULN Serum creatinine ≤ 2 times ULN Exclusion Criteria: * Presence of metastatic disease * Diabetes mellitus or glucose intolerance defined as a fasting glucose \>6mmol/l * Previous or concomitant other (non-breast cancer) malignancy within the previous 5 years * Presence of other non-malignant systemic diseases which may prevent prolonged follow-up * History of coronary artery disease or no history of previous coronary heart disease but at least two other coronary heart disease risk factors: LDL ≥8.8 mg/dL OR if fewer than two other coronary heart disease risk factors: LDL ≥10.45 mg/dL or total fasting cholesterol ≥ 13.2 mg/dL * Patients on hormone replacement therapy (HRT) within 4 weeks before trial treatment was initiated * Patients on breast cancer chemoprevention with anti-oestrogens if less than 18 months between stopping and diagnosis of breast cancer * Are at risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected blood * Known hypersensitivity to any component of testosterone * Unable to comply with study requirements * Taking the following concomitant medications at the screening visit-bisphosphonate, anti-cancer treatment other than anastrozole (this includes Herceptin). * Prolonged systemic corticosteroid treatment, except for topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local injections (e.g. intra-articular). Note: Short duration (\< 2 weeks) of systemic corticosteroids is allowed (e.g. for Chronic Obstructive Pulmonary Disease) but not within 1 month prior to randomisation. * Any investigational drugs * Systemic hormone replacement therapy * Pregnant or lactating women * Patients with history of fragility fracture or low BMD, osteoporosis or osteopenia * Known liver disease